Our Press Releases | Association for Accessible Medicines

Generic Prescription Drugs - Your Health. Our Commitment. #Take with Confidence

Karin Hessler Joins AAM as Assistant General Counsel

Mar 18, 2019 | Rachel Schwartz

Karin Hessler Joins AAM as Assistant General Counsel

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Mar 11, 2019 | Rachel Schwartz

AAM Statement in Response to Administration's FY 2020 Budget Proposal

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 7, 2019 | Rachel Schwartz

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 5, 2019 | Rachel Schwartz

AAM Statement on Dr. Scott Gottlieb's Departure

AAM Statement on Avalere Report

Feb 28, 2019 | Rachel Schwartz

New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines

Jonathan Kimball Joins AAM as Vice President, Trade & International Affairs

Feb 25, 2019 | Rachel Schwartz

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

Feb 19, 2019 | Rachel Schwartz

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

AAM Welcomes the Re-introduction of the PACED Act

Feb 13, 2019 | Rachel Schwartz

AAM Welcomes Re-Introduction of the PACED Act

Pass CREATES Act - lower prescription drug prices for patients

Feb 8, 2019 | Rachel Schwartz

Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act

Congress Should Reject Hatch-Waxman Act of 2019

Feb 7, 2019 | Rachel Schwartz

AAM: Congress Should Reject Hatch-Waxman Integrity Act of 2019

AAM Announces 2019 Board of Directors

Feb 4, 2019 | Jewel Smith

AAM Announces 2019 Board of Directors

Trump Targeting Backdoor Rebates - Lower Drug Prices

Feb 1, 2019 | Rachel Schwartz

AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates